A Subset of Osteosarcoma Bears Markers of CXCL12-Abundant Reticular Cells.

TitleA Subset of Osteosarcoma Bears Markers of CXCL12-Abundant Reticular Cells.
Publication TypeJournal Article
Year of Publication2022
AuthorsSosa BR, Wang Z, Healey JH, Hameed M, Greenblatt MB
JournalJBMR Plus
Volume6
Issue3
Paginatione10596
Date Published2022 Mar
ISSN2473-4039
Abstract

Currently, the cell of origin for osteosarcoma or other primary skeletal tumors is largely unknown. Recent reports identifying specific cell types comprising bone now newly enable investigation of this topic. Specifically, CXC motif chemokine 12 (CXCL12)-abundant reticular (CAR) cells are a specific skeletal stromal cell type that orchestrate the bone marrow microenvironment through cross-talk with hematopoietic and endothelial cells and a likely candidate cell of origin for at least a subset of primary skeletal tumors. Here, we analyze osteosarcomas via immunohistochemistry for known markers of CAR cells such as leptin receptor (LEPR), B-cell factor 3 (EBF3), CXCL12, and platelet-derived growth factor receptor alpha (PDGFRA). A large proportion of high-grade tumors expressed LEPR, PDGFRA, and EBF3 but not CXCL12. These data raise the hypothesis that CAR cells are the cell of origin of this osteoblastic osteosarcoma subset, a finding with implications for the cellular oncogenesis of primary osteosarcoma and the development of effective targeted therapies. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

DOI10.1002/jbm4.10596
Alternate JournalJBMR Plus
PubMed ID35309866
PubMed Central IDPMC8914147
Grant ListP30 CA008748 / CA / NCI NIH HHS / United States
Related Faculty: 
Matthew B. Greenblatt, M.D., Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700